期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

M蛋白与周围神经病变

Monoclonal protein and peripheral neuropathy
下载PDF
导出
摘要 M蛋白是由单克隆浆细胞分泌的单克隆免疫球蛋白,血中含有大量的单克隆免疫球蛋白又称为副蛋白血症。临床上,副蛋白血症与周围神经病变关系密切。本文从血液学角度,总结了M蛋白相关周围神经病变的发病机制、常见临床情况、诊断以及治疗,以期加深理解、为临床诊疗提供帮助。 Monoclonal protein is produced by monoclonal plasma cells. When much monoclonal protein emerges in blood,it is named as paraproteinemia. Clinically, paraproteinemia is closely related to peripheral neuropathy（ PN）. This article has reviewed the pathogenesis,general disorders,diagnosis and treatment of PN in order to offer help in clinical practice.
作者 郝渊渊 孙婉玲 Hao Yuanyuan;Sun Wanling(Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China)
机构地区 首都医科大学宣武医院血液科
出处 《首都医科大学学报》 CAS 北大核心 2018年第3期344-348,共5页 Journal of Capital Medical University
关键词 单克隆免疫球蛋白 周围神经病变 副蛋白血症 monoclonal immune globulin protein；peripheral neuropathy；paraproteinemia
分类号 R741 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献4

二级参考文献50

  • 1Delforge M, Blade J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues[J]. Lancet Oncol, 2010, 11(11) :1086-1095.
  • 2Mohty B, E1-Cheikh J, Yakoub-Agha I, et al. Peripheral neuropathy and new treatments for multiple myeloma:baekground and practical recommendations [ J ]. Haematologiea, 2010, 95 (2) :311-319.
  • 3Sonnevcld P, Jongen JL. Dealing with neuropathy in plasma-cell dyscrasias [ J ]. Hematology Am Soc Hematol Educ Program, 2010, 2010:423-430.
  • 4Morawska M, Grzasko N, Kostyra M, et al. Therapy-related peripheral neuropathy in multiple myeloma patients [ J/OL ]. Hematol Oucol, 2014 [ 2015-06-09]. http ://onlinelibrary. wiley. com/doi/10. 1002/hon. 2149/epdf. [ published online ahead of print November 14, 2014].
  • 5Dimopnulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma:subanalysis of the phase 3 VISTA study [ J ]. Eur J Haematol, 2011, 86( 1 ) :23-31.
  • 6Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase Ⅲ APEX trial in relapsed multiple myeloma: impact of a dose- modification guideline[J]. Br J Haematol, 2009, 144(6) :895- 903.
  • 7Hrusovsky I, Emmerich B, von Rohr A, et al. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multieenter survey in Germany and Switzerland [ J ]. Oncology, 2010, 79(3-4):247-254.
  • 8Petrucci MT, Giraldo P, Corradini P, et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma[ J]. Br J Haematol, 2013, 160 (5) :649-659.
  • 9Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy [ J ]. J Clin Oneol, 2009, 27(21 ) :3518-3525.
  • 10Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma [J]. Leukemia, 2012, 26(4) :595-608.

共引文献454

首都医科大学学报
2018年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部